{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-053953","form_type":"8-K","ticker":"DFTX","cik":"0001813814","company_name":"Definium Therapeutics, Inc.","filed_at":"2025-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.834494+00:00","generated_at":"2026-05-23T14:51:31.901402+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"MindMed doses first patient in Phase 3 Emerge study of MM120 ODT for MDD","bullets":["First patient dosed in Phase 3 Emerge study evaluating MM120 ODT 100 µg vs placebo in major depressive disorder.","Primary endpoint: change from baseline in MADRS score at Week 6; ~140 participants expected in U.S.","Topline data from the 12-week double-blind period anticipated in second half of 2026.","Emerge is the third Phase 3 study of MM120 ODT; Voyage and Panorama studies in GAD are already underway.","Phase 2b GAD study showed clinically and statistically significant MADRS improvements after single 100 µg dose."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-053953","json":"https://secwatch.observer/filing/0000950170-25-053953.json","markdown":"https://secwatch.observer/filing/0000950170-25-053953.md","text":"https://secwatch.observer/filing/0000950170-25-053953.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025053953/0000950170-25-053953-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025053953/mnmd-20250415.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T14:51:31.901402+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}